Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356)
Leichman L, Goldman B, Benedetti J, Billingsley K, Thomas C, Iqbal S, Lenz H, Blanke C, Gold P, Corless C. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). Journal Of Clinical Oncology 2009, 27: 4513-4513. DOI: 10.1200/jco.2009.27.15_suppl.4513.Peer-Reviewed Original ResearchExternal beam radiationPathologic complete responsePhase II trialOverall survivalEsophageal adenocarcinomaII trialSouthwest Oncology Group phase II trialGrade 3/4 toxicitiesMedian overall survivalNon-hematologic toxicitiesCentral pathology reviewPrimary tumor responseCooperative group trialsStandard of careTumor molecular profilesAcceptable toxicityFree survivalModality therapyComplete responseGastric cardiaNew regimensPathology reviewFuture trialsTumor responseSitu cancer